Search results
Showing 961 to 975 of 2186 results for guidelines
Evidence-based recommendations on lutetium (177Lu) oxodotreotide (Lutathera) for treating unresectable or metastatic neuroendocrine tumours in adults.
Tell us what matters to you, your organisation or your community.
Tell us what matters to you, your organisation or your community.
Summary of the evidence on rituximab for treating autoimmune haemolytic anaemia (AIHA) to inform local NHS planning and decision-making
myAIRVO2 for the treatment of chronic obstructive pulmonary disease (MIB161)
NICE has developed a medtech innovation briefing (MIB) on myAIRVO2 for the treatment of chronic obstructive pulmonary disease .
Kendall DL for ECG monitoring in people having cardiac surgery (MIB177)
NICE has developed a medtech innovation briefing (MIB) on Kendall DL for ECG monitoring in people having cardiac surgery .
NICE has developed a medtech innovation briefing (MIB) on RenalSense Clarity RMS for acute kidney injury .
Find out more about the NICE technology appraisal advisory committee B members and their registered interests
Find out more about the NICE technology appraisal advisory committee B members and their registered interests
Carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma (TA121)
Evidence-based recommendations on carmustine implants (Gliadel) and temozolomide for treating newly diagnosed high-grade glioma in adults.
View recommendations for TA121Show all sections
NICE has developed a medtech innovation briefing (MIB) on LQD Spray for treating acute and chronic wounds .
Xpert GBS test for the intrapartum detection of group B streptococcus (MIB28)
NICE has developed a medtech innovation briefing (MIB) on Xpert GBS test for the intrapartum detection of group B streptococcus
Non-Hodgkin's lymphoma: rituximab subcutaneous injection (ESNM46)
Summary of the evidence on rituximab subcutaneous injection for non-Hodgkin's lymphoma in adults to inform local NHS planning and decision-making
Evidence-based recommendations on the CoaguChek XS system for self-monitoring coagulation status in adults and children. The recommendations originally included the InRatio2 PT/INR, but this was withdrawn from the market in October 2016 and is not currently available.
Our centralised approach to prioritising our guidance topics ensures that we produce guidance that's relevant, timely, accessible, and has demonstrable impact.